Patents by Inventor Ana C. Puhl

Ana C. Puhl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF PYRONARIDINE, TILORONE, AND QUINACRINE AGAINST MARBURG VIRUS AND OTHER VIRUS INFECTIONS
    Publication number: 20240009183
    Abstract: Methods of treating or preventing diseases caused by viral infections via the administration of pyronaridine, quinacrine, and/or tilorone are described. The viral infections can be caused by viruses such as Marburg virus (MARV), Chikungunya virus (CHIKV), norovirus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Nipah virus.
    Type: Application
    Filed: July 10, 2023
    Publication date: January 11, 2024
    Applicant: Collaborations Pharmaceuticals, Inc.
    Inventors: Sean Ekins, Thomas R. Lane, Ana C. Puhl
  • THE ANTIVIRAL DRUG TILORONE IS A POTENT AND SELECTIVE INHIBITOR OF ACETYLCHOLINESTERASE
    Publication number: 20230330045
    Abstract: The identification of new acetylcholinesterase (AChE) inhibitors is described. For example, tilorone was newly identified as an AChE inhibitor by use of a machine learning model followed by in vitro screening. The new AChE inhibitors can selectively inhibit AChE compared to butyrylcholinesterase (BuChE). Methods of inhibiting AChE and of treating or preventing diseases, disorders, and conditions treatable or preventable by AChE inhibition are also described. For example, methods of treating and/or preventing certain dermatological conditions and organophosphorous or nerve agent poisoning are described.
    Type: Application
    Filed: September 16, 2021
    Publication date: October 19, 2023
    Inventors: Patricia A. Vignaux, Ana C. Puhl Rubio, Sean Ekins
  • Use of pyronaridine, tilorone, and quinacrine against Marburg virus and other virus infections
    Patent number: 11696914
    Abstract: Methods of treating or preventing diseases caused by viral infections via the administration of pyronaridine, quinacrine, and/or tilorone are described. The viral infections can be caused by viruses such as Marburg virus (MARV), Chikungunya virus (CHIKV), norovirus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Nipah virus.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: July 11, 2023
    Assignee: Collaborations Pharmaceuticals, Inc.
    Inventors: Sean Ekins, Thomas R. Lane, Ana C. Puhl Rubio